Cargando…
Harmonization of CSF and imaging biomarkers for Alzheimer’s disease biomarkers: need and practical applications for genetics studies and preclinical classification
INTRODUCTION: In Alzheimer’s disease (AD) research, cerebrospinal fluid (CSF) Amyloid beta (Aβ), Tau and pTau are the most accepted and well validated biomarkers. Several methods and platforms exist to measure those biomarkers which leads to challenges in combining data across studies. Thus, there i...
Autores principales: | Timsina, Jigyasha, Ali, Muhammad, Do, Anh, Wang, Lihua, Sung, Yun Ju, Cruchaga, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245826/ https://www.ncbi.nlm.nih.gov/pubmed/37292823 http://dx.doi.org/10.1101/2023.05.24.542118 |
Ejemplares similares
-
CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022) -
Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
por: Neumann, Alexander, et al.
Publicado: (2023) -
Unique genetic architecture of CSF and brain metabolites pinpoints the novel targets for the traits of human wellness
por: Wang, Ciyang, et al.
Publicado: (2023) -
Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
por: Giangrande, Chiara, et al.
Publicado: (2023) -
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
por: Mankhong, Sakulrat, et al.
Publicado: (2022)